Therapy With Verapamil or Carvedilol in Chronic Heart Failure

Status Recruiting

Clinical Trial Summary

The aim of this study is to compare the effect of treatment with verapamil or carvedilol on long-term outcomes in stable, chronic heart failure secondary to non-ischemic cardiomyopathy.

Clinical Trial Description

Heart failure, irrespective of its etiology may be viewed as a progressive disorder initiated by a different events and sustained by a multifaceted pathophysiological mechanisms. Regardless of the nature of the initiating events and optimized therapy used, loss of functioning cardiac myocytes developed and the disease progressed. One potential explanation for such progression is that not all pathological mechanisms underlying the disease are antagonized enough by currently used therapeutic strategy. Accordingly, impaired myocardial perfusion secondary to microvascular dysfunction has been postulated to play a major role in the progression of heart failure despite standard therapy for heart failure. It has been hypothesized that diffuse subendocardial ischemia due to altered coronary physiology may contribute to the global cardiac dysfunction seen in heart failure patients. Accordingly, coronary endothelial dysfunction at the microvascular and epicardial level in patients with acute-onset idiopathic dilated cardiomyopathy and chronic congestive heart failure has been reported. Thus, taking all mentioned above into account, the improvement in endothelial function and diminishing of subendocardial ischemia with calcium antagonists may be promising in terms of using these drugs for therapy of patients with stable chronic heart failure. The previous randomized study (5) and our long-term pilot study support this point of view. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00374465
Study type	Interventional
Source	Medical University of Silesia
Contact	Jan Wodniecki, MD, PhD
Phone	+48 32 2716471
Email	wojnicz@dom.zabrze.pl
Status	Recruiting
Phase	Phase 4
Start date	January 2006
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05564689` - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
Recruiting	`NCT04982081` - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection	Phase 1
Not yet recruiting	`NCT04703751` - Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents	N/A
Recruiting	`NCT01157299` - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO	N/A
Completed	`NCT00765518` - Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)	Phase 2
Completed	`NCT02115581` - Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy	Phase 4
Recruiting	`NCT04246450` - Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy	N/A
Recruiting	`NCT05799833` - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting	`NCT01914081` - Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside	Phase 3
Recruiting	`NCT02915718` - A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy	N/A
Recruiting	`NCT03061994` - Metabolomic Study of All-age Cardiomyopathy	N/A
Completed	`NCT03893760` - Assessment of Right Ventricular Function in Advanced Heart Failure
Not yet recruiting	`NCT01219452` - Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy	Phase 1/Phase 2
Recruiting	`NCT02175836` - Arrhythmia Prediction Trial	N/A
Active, not recruiting	`NCT00962364` - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting	`NCT05026112` - The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
Recruiting	`NCT05237323` - Micophenolate Mofetil Versus Azathioprine in Myocarditis	Phase 3
Recruiting	`NCT04649034` - Intraventricular Stasis In Cardiovascular Disease
Suspended	`NCT03071653` - Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study	Phase 2
Completed	`NCT02619825` - Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.